{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:09:42Z","timestamp":1783177782843,"version":"3.54.6"},"reference-count":31,"publisher":"Pharmaceutical Society of Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,4,24]]},"DOI":"10.1248\/bpb.b24-00784","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T22:07:16Z","timestamp":1745446036000},"page":"415-421","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the Influence of the National Action Plan on Antimicrobial Resistance and the COVID-19 Pandemic on the Consumption of Broad-Spectrum Antimicrobial and Anti-methicillin-resistant &lt;i&gt;Staphylococcus aureus&lt;\/i&gt; Agents"],"prefix":"10.1248","volume":"48","author":[{"given":"Ryota","family":"Goto","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, 5 Misasagi-Nakauchi-cho, Yamashina-ku, Kyoto 607\u20138414, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Inose","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, 5 Misasagi-Nakauchi-cho, Yamashina-ku, Kyoto 607\u20138414, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Koizumi","sequence":"additional","affiliation":[{"name":"AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, 1\u201321\u20131 Toyama, Shinjuku-ku, Tokyo 162\u20138655, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Sawada","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, 5 Misasagi-Nakauchi-cho, Yamashina-ku, Kyoto 607\u20138414, Japan"},{"name":"Department of Pharmacy, Federation of National Public Service Personnel Mutual Aid Associations, Hirakata Kohsai Hospital, 1\u20132\u20131 Fujisaka Higashimachi, Hirakata, Osaka 573\u20130153, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ishikane","sequence":"additional","affiliation":[{"name":"AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, 1\u201321\u20131 Toyama, Shinjuku-ku, Tokyo 162\u20138655, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[{"name":"AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, 1\u201321\u20131 Toyama, Shinjuku-ku, Tokyo 162\u20138655, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Muraki","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, 5 Misasagi-Nakauchi-cho, Yamashina-ku, Kyoto 607\u20138414, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Christaki E, Marcou M, Tofarides A. Antimicrobial resistance in bacteria: mechanisms, evolution, and persistence. <i>J. Mol. Evol.<\/i>, <b>88<\/b>, 26\u201340 (2020).","DOI":"10.1007\/s00239-019-09914-3"},{"key":"2","unstructured":"2) WHO. \u201cGlobal action plan on antimicrobial resistance.\u201d: &lt;https:\/\/www.who.int\/publications\/i\/item\/9789241509763&gt;, accessed 27 December, 2024."},{"key":"3","unstructured":"3) Ministry of Health, Labour and Welfare. \u201cNational action plan on antimicrobial resistance 2016-2020.\u201d: &lt;https:\/\/www.mhlw.go.jp\/content\/10900000\/0000138942.pdf&gt;, accessed 21 August, 2024."},{"key":"4","unstructured":"4) Ministry of Health, Labour and Welfare. \u201cNational action plan on antimicrobial resistance 2023-2027.\u201d: &lt;https:\/\/www.mhlw.go.jp\/content\/10900000\/001096228.pdf&gt;, accessed 27 December, 2024."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. <i>BMC Infect. Dis.<\/i>, <b>14<\/b>, 13 (2014).","DOI":"10.1186\/1471-2334-14-13"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Muraki Y, Yagi T, Tsuji Y, Nishimura N, Tanabe M, Niwa T, Watanabe T, Fujimoto S, Takayama K, Murakami N, Okuda M. Japanese antimicrobial consumption surveillance: first report on oral and parenteral antimicrobial consumption in Japan (2009\u20132013). <i>J. Glob. Antimicrob. Resist.<\/i>, <b>7<\/b>, 19\u201323 (2016).","DOI":"10.1016\/j.jgar.2016.07.002"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Ishikane M, Kusama Y, Tanaka C, Hayakawa K, Kuwahara T, Ohmagari N. Epidemiology of antimicrobial VCM among nursing homes in Japan, 2016: a pilot study. <i>Jpn. J. Infect. Dis.<\/i>, <b>73<\/b>, 293\u2013295 (2020).","DOI":"10.7883\/yoken.JJID.2019.476"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ono A, Ishikane M, Kusama Y, Tanaka C, Ono S, Tsuzuki S, Muraki Y, Yamasaki D, Tanabe M, Ohmagari N. The first national survey of antimicrobial use among dentists in Japan from 2015 to 2017 based on the national database of health insurance claims and specific health checkups of Japan. <i>PLOS ONE<\/i>, <b>15<\/b>, e0244521 (2020).","DOI":"10.1371\/journal.pone.0244521"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ebisui A, Inose R, Kusama Y, Koizumi R, Kawabe A, Ishii S, Goto R, Ishikane M, Yagi T, Ohmagari N, Muraki Y. Trends in antipseudomonal agent use based on the 2006 to 2015 sales data in Japan. <i>Biol. Pharm. Bull.<\/i>, <b>44<\/b>, 816\u2013821 (2021).","DOI":"10.1248\/bpb.b21-00004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Goto R, Inose R, Kusama Y, Kawabe A, Ishii S, Ebisui A, Ishikane M, Yagi T, Ohmagari N, Muraki Y. Trends of the use of anti-methicillin-resistant Staphylococcus aureus agents in Japan based on sales data from 2006 to 2015. <i>Biol. Pharm. Bull.<\/i>, <b>43<\/b>, 1906\u20131910 (2020).","DOI":"10.1248\/bpb.b20-00605"},{"key":"11","unstructured":"11) The Eight Societies Joint Committee for enhancement of antimicrobial stewardship. \u201cGuidance for implementing an antimicrobial stewardship program in Japan.\u201d: &lt;https:\/\/www.chemotherapy.or.jp\/uploads\/files\/guideline\/kobiseibutuyaku_guidance.pdf&gt;, accessed 27 December, 2024."},{"key":"12","unstructured":"12) Ministry of Health. Labour and Welfare. \u201cRevision of Medical Fees in fiscal year 2018.\u201d: &lt;https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000188411.html&gt;, accessed 27 December, 2024."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Maeda M, Miyake T, Inose R, Ueda S, Matsugi KI, Muraki Y, Kitahara T. Bibliometric analysis of pharmacist\u2019s research on antimicrobial stewardship in Japan: an interrupted time series analysis on the implementation of the certification system for infection control pharmacists. <i>J. Pharm. Health Care Sci.<\/i>, <b>7<\/b>, 38 (2021).","DOI":"10.1186\/s40780-021-00223-w"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kinoshita R, Jung SM, Kobayashi T, Akhmetzhanov AR, Nishiura H. Epidemiology of coronavirus disease 2019 (COVID-19) in Japan during the first and second waves. <i>Math. Biosci. Eng.<\/i>, <b>19<\/b>, 6088\u20136101 (2022).","DOI":"10.3934\/mbe.2022284"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Yamasaki D, Tanabe M, Muraki Y, Kato G, Ohmagari N, Yagi T. The first report of Japanese antimicrobial use measured by national database based on health insurance claims data (2011-2013): comparison with sales data, and trend analysis stratified by antimicrobial category and age group. <i>Infection<\/i>, <b>46<\/b>, 207\u2013214 (2018).","DOI":"10.1007\/s15010-017-1097-x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Sawada K, Inose R, Goto R, Nakatani T, Kono S, Muraki Y. Effectiveness of noncertified pharmacist-led antimicrobial stewardship programs in a medium-sized hospital without an infectious disease specialist: a retrospective pre-post study. <i>Open Forum Infect. Dis.<\/i>, <b>10<\/b>, ofad116 (2023).","DOI":"10.1093\/ofid\/ofad116"},{"key":"17","unstructured":"17) AMR Clinical Reference Center. \u201cRules for creating an antimicrobial master.\u201d: &lt;https:\/\/amrcrc.ncgm.go.jp\/surveillance\/030\/20241101_rule.pdf&gt;, accessed 21 August, 2024."},{"key":"18","unstructured":"18) Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. <i>Int. J. Epidemiol.<\/i>, <b>46<\/b>, 348\u2013355 (2017)."},{"key":"19","unstructured":"19) Bernal JL, Cummins S, Gasparrini A. Corrigendum to: interrupted time series regression for the evaluation of public health interventions: a tutorial. <i>Int. J. Epidemiol.<\/i>, <b>49<\/b>, 1414 (2020)."},{"key":"20","unstructured":"20) R Core Team. _R. \u201cA Language and Environment for Statistical Computing_. R Foundation for Statistical Computing, Vienna, Austria (2024).\u201d: &lt;https:\/\/www.R-project.org\/&gt;."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Makiyama K, Kawashima T, Nomura S, Eguchi A, Yoneoka D, Tanoue Y, Kawamura Y, Sakamoto H, Gilmour S, Shi S, Matsuura K, Uryu S, Hashizume M. Trends in healthcare access in Japan during the first wave of the COVID-19 pandemic, up to June 2020. <i>Int. J. Environ. Res. Public Health<\/i>, <b>18<\/b>, 3271 (2021).","DOI":"10.3390\/ijerph18063271"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Tanoue Y, Ghaznavi C, Kawashima T, Eguchi A, Yoneoka D, Nomura S. Changes in health care access during the COVID-19 pandemic: estimates of National Japanese Data, June 2020\u2013October 2021. <i>Int. J. Environ. Res. Public Health<\/i>, <b>19<\/b>, 8810 (2022).","DOI":"10.3390\/ijerph19148810"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Itoh N, Akazawa N, Kanawaku E, Murakami H, Ishibana Y, Kawamura D, Kawabata T, Mori K, Kodama EN, Ohmagari N. Effects of infectious disease consultation and antimicrobial stewardship program at a Japanese cancer center: an interrupted time-series analysis. <i>PLoS One<\/i>, <b>17<\/b>, e0263095 (2022).","DOI":"10.1371\/journal.pone.0263095"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Inoue K, Kobayashi S, Sato K, Kanno H, Kantou R, Naganuma Y, Kawamura N, Oike Y, Kobayashi M, Yanai M, Suzuki A, Kurai H, Miyairi I, Kutsuna S, Gu Y. Regional antimicrobial stewardship program in a provincial medical zone in Japan: a multifaceted approach. <i>Jpn. J. Infect. Dis.<\/i>, <b>75<\/b>, 347\u2013354 (2022).","DOI":"10.7883\/yoken.JJID.2021.577"},{"key":"25","unstructured":"25) Ministry of Health, Labour and Welfare. \u201cNippon AMR one health report 2022.\u201d: &lt;https:\/\/www.mhlw.go.jp\/content\/10900000\/001158348.pdf&gt;, accessed 21 August, 2024."},{"key":"26","unstructured":"26) AMR Clinical Reference Center. \u201cJ-SIPHE annual report 2021.\u201d: &lt;https:\/\/j-siphe.ncgm.go.jp\/files\/JSIPHE_AnnualReport_2021en.pdf&gt;, accessed 21 August, 2024."},{"key":"27","unstructured":"27) National Institute of Infectious Diseases. \u201cSubmission of MRSA infections under the infectious disease control law in 2021.\u201d: &lt;https:\/\/www.niid.go.jp\/niid\/ja\/mrsa-m\/mrsa-idwrs\/12268-mrsa-230926.html&gt;, accessed 21 August, 2024."},{"key":"28","unstructured":"28) Committee for the preparation of treatment guidelines for MRSA infections. \u201cPractical guidelines for the management and treatment of infections caused by MRSA, 2019 Edition.\u201d: &lt;https:\/\/www.chemotherapy.or.jp\/uploads\/files\/guideline\/guideline_mrsa_2019.pdf&gt;, accessed 21 August, 2024."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Nakatani S, Ohara T, Ashihara K, <i>et al.<\/i> JCS 2017 guideline on prevention and treatment of infective endocarditis. <i>Circ. J.<\/i>, <b>83<\/b>, 1767\u20131809 (2019).","DOI":"10.1253\/circj.CJ-19-0549"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Seaton RA, Menichetti F, Dalekos G, Beiras-Fernandez A, Nacinovich F, Pathan R, Hamed K. Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European Cubicin(\u00ae) outcomes registry and experience. <i>Adv. Ther.<\/i>, <b>32<\/b>, 1192\u20131205 (2015).","DOI":"10.1007\/s12325-015-0267-4"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Kusama Y, Muraki Y, Tanaka C, Koizumi R, Ishikane M, Yamasaki D, Tanabe M, Ohmagari N. Characteristics and limitations of national antimicrobial surveillance according to sales and claims data. <i>PLOS ONE<\/i>, <b>16<\/b>, e0251299 (2021).","DOI":"10.1371\/journal.pone.0251299"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/4\/48_b24-00784\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T03:23:48Z","timestamp":1745637828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/4\/48_b24-00784\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b24-00784","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"article-number":"b24-00784"}}